Crossmark

Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)

Crossref DOI link: https://doi.org/10.1186/S12882-018-1128-6

Published: 2018-12

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

Authors

Schimpf, Judith Isabel

Klein, Till

Fitzner, Christina

Eitner, Frank

Porubsky, Stefan

Hilgers, Ralf-Dieter

Floege, Jürgen

Groene, Hermann-Josef

Rauen, Thomas http://orcid.org/0000-0002-6544-8901
License Information

Text and Data Mining valid from 2018-11-19
More Information

Article History

Received: 21 December 2017

Accepted: 31 October 2018

First Online: 19 November 2018

Ethics approval and consent to participate

: The original study protocol of STOP-IgAN was amended in 2009 and allowed to retrieve all available original renal biopsies from randomized trial participants. Written informed consent for re-assessment of available kidney biopsies was obtained from all patients included in this secondary substudy. The STOP-IgAN trial as well as the current substudy were approved by the Ethics Committee at the RWTH Aachen University Hospital (reference number 159/07).

: Not applicable.

: J. Floege has received consultant honoraria from Omeros, USA and Pharmalink, Sweden, and investigator fees from Anthera Pharmaceuticals Inc., USA. The other authors declare no competing financial interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.